EGFR and non-small cell lung carcinoma: Small molecule inhibitors that target the epidermal growth factor receptor (EGFR) tyrosine kinase, such as gefitinib and osimertinib (AZD9291), have ushered in a new era in the treatment of NSCLC patients with activating EGFR mutations [177].